Table 1.
Clinical characteristics and laboratory findings of the SARS and Control groups in 2018.
SARS n = 53 | Control n = 45 | P value | |
---|---|---|---|
Male sex (%) | 8 (15.09%) | 10 (22.22%) | 0.364 |
Age (years) | 46 (40-51) | 44 (40-48) | 0.337 |
Comorbidities, n (%) | |||
Heart disfunction | 1 (2.0%) | 1 (2.4%) | 1.000 |
Chronic renal disease | 0 (0.0%) | 0 (0.0%) | – |
Liver disease | 0 (0.0%) | 0 (0.0%) | – |
Diabetes mellitus | 2 (4.1%) | 2 (4.8%) | 1.000 |
High pressure | 6 (12.2%) | 5 (11.9%) | 0.960 |
Pulmonary fibrosis | 18 (36.7%) | 0 (0.0%) | <0.0001 |
Laboratory findings | |||
White blood cell (×103/mm3) | 5.72 ± 0.24 | 5.89 ± 0.21 | 0.614 |
Neutrophils(×103/mm3) | 3.19 ± 0.16 | 3.26 ± 0.15 | 0.740 |
Lymphocytes(×103/mm3) | 1.74 (1.41-2.34) | 1.93 (1.68-2.28) | 0.420 |
Hemoglobin level (g/dL) | 135.36 ± 2.00 | 138.73 ± 2.30 | 0.269 |
Platelet count (×103/mm3) | 269.00 (230.50-309.50) | 252.00 (234.00-293.50) | 0.408 |
Glucose (mmol/L) | 5.09 (4.78-5.41) | 5.21 (4.81-5.64) | 0.0.32 |
Albumin (g/L) | 44.28 ± 0.32 | 45.36 ± 0.36 | 0.073 |
ALT (U/L) | 17.00 (12.00-21.50) | 17.00 (13.00-23.00) | 0.892 |
AST (U/L) | 18.00 (16.00-24.00) | 18.00 (16.00-21.00) | 0.429 |
LDH (U/L) | 159.13 ± 3.34 | 165.84 ± 4.00 | 0.197 |
CREA (µmol/L) | 56.00 (52.00-56.50) | 54.00 (47.00-64.00) | 0.175 |
IgA (g/L) | 2.05 (1.69-3.05) | 2.17 (1.56-2.54) | 0.503 |
IgG (g/L) | 12.30(10.90-13.45) | 13.00 (11.20-14.65) | 0.059 |
IgM (g/L) | 0.95 (0.71-1.15) | 1.09 (0.76-1.37) | 0.163 |
C3 (g/L) | 0.92 ± 0.02 | 0.95 ± 0.03 | 0.417 |
SARS group: convalescents who were infected with SARS-CoV in 2003; Control group: close contacts of SARS group who were not infected with SARS-CoV in 2003. Data are presented as means ± standard error from the mean, or median (interquartile range) or n (%). ALT, Alanine aminotransferase; AST, Aspartate aminotransferase; LDH, lactate dehydrogenase; CREA, Creatinine; IgA, immunoglobin A; IgG, immunoglobin G; IgM, immunoglobin M; C3, complement C3.
The bold value mean that P value < 0.05 and were statistically significant.